JPMorgan analyst Brian Cheng lowered the firm’s price target on TG Therapeutics (TGTX) to $46 from $49 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TGTX:
- Buy Rating on Briumvi Driven by Strong Commercial Momentum, 2026 Growth Outlook, and Underappreciated Autoimmune Pipeline Optionality
- TG Therapeutics price target raised to $39 from $37 at Goldman Sachs
- Midday Fly By: Big banks report mixed quarterly results
- TG Therapeutics rises 12.2%
- Unusually active option classes on open January 14th